CSL Ltd Annual Report 2021

‘Great science leads to great medicines. Great medicines don’t just happen by themselves.’ Dr Andrew Nash , Chief Scientific Officer and Senior Vice President, Head of Research Science has always been at the forefront of pioneering medical innovation. Where medical researchers in the past have unassumingly endeavoured to advance the next theory, to uncover the next breakthrough, and to bring life-changing medicines to people who need them, they are now doing so under close global attention as a result of the COVID-19 pandemic – and they are delivering. Innovative science and discovery form the core of our R&D efforts and approach to drug development. What stands CSL in good stead is our quantitative approach to understanding the nature and biology of a disease at a molecular and cellular level. Over the past year, whilst navigating the complex nature of a pandemic-ravaged world, CSL’s world-class scientists have demonstrated an ability and agility to respond quickly and innovatively to the ever-changing social, economic and healthcare challenges brought on by the COVID-19 pandemic. Our focus remains the same: to deliver on our promise to patients by ensuring that high-quality science translates through to the discovery and development of new life- changing medicines for those who need them. CSL’s philosophy of global collaboration underpins our presence within research hubs and precincts around the world. Strong global research networks and collaborations are an integral part of our global R&D business as they provide valuable opportunities for our scientists to interact, discover and innovate with external partners. We continue to identify and expand our network of collaborators, both academic and industry-based, to enrich external innovation and thinking. Expanding our R&D footprint CSL continues to advance its global programs and teams and expand its R&D footprint. CSL has: • access to worldwide, leading innovation that leverages knowledge from CSL employees as well as from research and medical institutions/alliances local to CSL’s R&D centres; • 1,700 scientists in nine countries, working in integrated teams; and • R&D centres located in leading biomedical locations including in Melbourne, Australia; Bern, Switzerland; Marburg, Germany; Pasadena, California, US; King of Prussia, Pennsylvania, US; Amsterdam, Netherlands; and Cambridge, Massachusetts, US. One of the benefits of having a collaborative global R&D organisation with R&D centres strategically situated in close proximity to world-class universities, institutes and biomedical precincts, is that it allows us to efficiently access external global talent and foster global innovation. The following are some notable examples of our investment in our strategic growth over the last 12 months. • Construction of CSL’s new global headquarters in the Parkville Biomedical Precinct in Melbourne, Australia commenced in July 2020. Construction is expected to be complete toward the end of 2022 with occupation of the new building planned for early 2023. The facility will house around 800 employees, including product development teams from both CSL and Seqirus R&D, and include leading-edge laboratories along with space for external collaborators, innovators and start-ups. The facility is just 500m from the Bio21 Institute, where CSL’s early stage research team has been based for over 10 years, and will further enable collaboration with other researchers in this multidisciplinary biomedical precinct. • The new R&D campus, in Marburg, Germany will open its doors mid-2022 and will be the new home for CSL Behring R&D employees as well as academic partners and collaborators. In early 2021, CSL signed a lease to expand operations at CSL Behring’s R&D facility in Pasadena, California, US and add a dedicated office and laboratory facilities for cell manufacturing product development. Construction of the new R&D campus in Marburg, Germany commenced in November 2019 and since then over 60,000m 2 of earth have been removed, over 3,630kg of steel used, 31,000,000L of concrete poured and over 450,000m of cabling installed. CSL Limited Annual Report 2020/21 24 7 Powered by Innovation